Identification of biological relevant minor histocompatibility antigens within the B-lymphocyte-derived HLA-ligandome using a reverse immunology approach

Clinical Cancer Research

Volumn 21, Issue 9, 2015, Pages 2177-2186

  Hombrink, Pleun ^a   Hassan, Chopie ^a   Kester, Michel G D ^a   Jahn, Lorenz ^a   Pont, Margot J ^a   De Ru, Arnoud H ^a   Van Bergen, Cornelis A M ^a   Griffioen, Marieke ^a   Falkenburg, J H Frederik ^a   Van Veelen, Peter A ^a   Heemskerk, Mirjam H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; B LYMPHOCYTE ANTIGEN DERIVED HLA LIGANDOME; MINOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN LB CLYBL 1Y; MINOR HISTOCOMPATIBILITY ANTIGEN LB TEP1 1S; UNCLASSIFIED DRUG; EPITOPE;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE FREQUENCY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOLOGICAL PROCEDURES; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; PRIORITY JOURNAL; REVERSE IMMUNOLOGY APPROACH; T LYMPHOCYTE; ALGORITHM; ALLOGRAFT; B LYMPHOCYTE; DNA MICROARRAY; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; TANDEM MASS SPECTROMETRY;

ALGORITHMS; ALLOGRAFTS; B-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; T-LYMPHOCYTES; TANDEM MASS SPECTROMETRY;

EID: 84942234520     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2188     Document Type: Article

References (30)

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-9.
2. Falkenburg JH, van de Corput L, Marijt EW, Willemze R. Minor histocom-patibility antigens in human stem cell transplantation. Exp Hematol 2003;31:743-51.
3. Feng X, Hui KM, Younes HM, Brickner AG. Targeting minor histocompat-ibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol 2008;29:624-32.
4. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997;157:125-40.
5. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007;109: 1355-62.
6. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009;373:1550-61.
7. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998;91:2197-207.
8. Bleakley M, Riddell SR. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol 2011;89:396-407.
9. van Bergen CA, Rutten CE, van der Meijden ED, van Luxemburg-Heijs SA, Lurvink EG, Houwing-Duistermaat JJ, et al. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. Cancer Res 2010;70:9073-83.
10. Hombrink P, Hadrup SR, Bakker A, Kester MG, Falkenburg JH, von dem Borne PA, et al. High-throughput identification of potential minor histo-compatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One 2011;6:e22523.
11. Ofran Y, Kim HT, Brusic V, Blake L, Mandrell M, Wu CJ, et al. Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encodedminor histocompatibility epitopes.Clin Cancer Res 2010;16:1642-51.
12. Popovic J, Li LP, Kloetzel PM, Leisegang M, Uckert W, Blankenstein T. The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood 2011;118:946-54.
13. Hombrink P, Hassan C, Kester MG, de Ru AH, Van Bergen CA, Nijveen H, et al. Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach. J Immunol 2013;190:3869-77.
14. Gilchuk P, Spencer CT, Conant SB, Hill T, Gray JJ, Niu X, et al. Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest 2013;123:1976-87.
15. Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, et al. The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics 2013;12:1829-43.
16. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476-80.
17. van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM, et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood 2007;109: 4089-96.
18. Nijveen H, Kester MG, Hassan C, Viars A, de Ru AH, de JM, et al. HSPVdb-the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands. Immunogenetics 2011;63:143-53.
19. Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol 2000;165:6229-34.
20. Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 2006;1:1120-32.
21. Eijsink C, Kester MG, Franke ME, Franken KL, Heemskerk MH, Claas FH, et al. Rapid assessment of the antigenic integrity of tetrameric HLA complexes by human monoclonal HLA antibodies. J Immunol Methods 2006;315:153-61.
22. Nauta AJ, de HS, Bottazzi B, Mantovani A, Borrias MC, Aten J, et al. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int 2005; 67:543-53.
23. Griffioen M, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Lurvink EG, Kester MG, et al. Identification of 4 novel HLA-B∗40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity. Haematologica 2012;97:1196-204.
24. Kremer AN, Van Der Meijden ED, Honders MW, Goeman JJ, Wiertz EJ, Falkenburg JH, et al. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO. Blood 2012;120:3246-55.
25. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, et al. Design and use of conditional MHC class I ligands. Nat Med 2006; 12:246-51.
26. Macdonald WA, Chen Z, Gras S, Archbold JK, Tynan FE, Clements CS, et al. T cell allorecognition via molecular mimicry. Immunity 2009;31:897-908.
27. Hombrink P, Raz Y, Kester MG, de BR, Weissbrich B, von dem Borne PA, et al. Mixed functional characteristics correlating with TCR-ligand k-rate of MHC-tetramer reactive T cells within the naive T-cell repertoire. Eur J Immunol 2013. Nov;43(11):3038-50
28. Ford ML, Koehn BH, Wagener ME, Jiang W, Gangappa S, Pearson TC, et al. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement forcostimulation. J Exp Med 2007;204:299-309.
29. Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, Kedl RM, et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 2007;27:203-13.
30. Nauerth M, Weissbrich B, Knall R, Franz T, Dossinger G, Bet J, et al. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med 2013;5:192ra87.